Tumor desialylation surpasses anti‐PD‐L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer

Documenti analoghi

• Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
  di: Shuling Shi, et al.
  Pubblicazione: (2024)
• CAPability‐01: Success of anti‐PD‐1, HDAC inhibitor, and anti‐VEGF combination in colorectal cancer
  di: Yujie Tan, et al.
  Pubblicazione: (2024)
• Combination therapy for colorectal cancer with anti-PD-L1 and cancer vaccine: A multiscale mathematical model of tumor-immune interactions
  di: Li, Chenghang, et al.
  Pubblicazione: (2026)
• Lecciones aprendidas sobre el potencial y las limitantes para el desarrollo de alternativas al uso insostenible de la carne de monte en bosques tropicales y sub-tropicales a nivel mundial
  di: Nathalie van Vliet
  Pubblicazione: (2013)
• Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study
  di: Manja Bloem, et al.
  Pubblicazione: (2024)